Kerendia (finerenone) - Bayer
hydroxyurea - Generic mfg.
Jakafi (ruxolitinib) - Incyte
Jardiance (empagliflozin) - Eli Lilly, Boehringer Ingelheim
losartan - Generic mfg.
Myeloproliferative Nephropathy Unmasks a Hematologic Diagnosis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1250; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Hydroxyurea was initiated without response; he switched to ruxolitinib with improvement. With cytoreductive therapy and treatment of DN with empagliflozin, losartan, finerenone, and semaglutide, UACR fell to 189 mg/g with stable creatinine. Discussion In cases of renal biopsy findings suggestive of myeloproliferative nephropathy without definitively diagnosed myeloproliferative neoplasm, additional hematologic testing should be pursued." 
Atypical Hemolytic Uremic Syndrome • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hematological Disorders • Metabolic Disorders • Myeloproliferative Neoplasm • Nephrology • Polycythemia Vera • Renal Disease • CFHR3 • JAK2 • LAMA5
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4551148
 
Samira Mahesh Samant; Megan L. Troxell; Graham E. Abra
 
Oct 2, 2026
 
Prev Next